News
Could This News Upset Vertex Pharmaceuticals' Prospects in the Billion-Dollar Pain Management Market?
Vertex Pharmaceuticals (NASDAQ: VRTX) is the global leader in cystic fibrosis (CF) treatment, and that specialty has helped it generate billions of dollars in earnings. But the company has also
Vertex Pharmaceuticals Will Use $100 Million to Tank Its Own Market Share. Here's Why That's a Smart Move.
Hot off the approval of its gene therapy for a pair of rare hereditary blood disorders, Vertex Pharmaceuticals (NASDAQ: VRTX) will soon have another therapy up for approval, and the financial
Vertex Pharmaceuticals Will Use $100 Million to Tank Its Own Market Share. Here's Why That's a Smart Move.
Hot off the approval of its gene therapy for a pair of rare hereditary blood disorders, Vertex Pharmaceuticals (NASDAQ: VRTX) will soon have another therapy up for approval, and the financial
Vertex Pharmaceuticals Will Use $100 Million to Tank Its Own Market Share. Here's Why That's a Smart Move.
Hot off the approval of its gene therapy for a pair of rare hereditary blood disorders, Vertex Pharmaceuticals (NASDAQ: VRTX) will soon have another therapy up for approval, and the financial
Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?
Dividends never go out of style, but some dividend stocks can. That's how some investors might feel about Pfizer (NYSE: PFE) and Bristol Myers Squibb (NYSE: BMY) these days. Both companies have
Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?
Dividends never go out of style, but some dividend stocks can. That's how some investors might feel about Pfizer (NYSE: PFE) and Bristol Myers Squibb (NYSE: BMY) these days. Both companies have
If You Invested $20,000 in Amgen in 2014, This Is How Much You Would Have Today
Amgen (NASDAQ: AMGN) is one of the largest drug manufacturers in the world, with a market cap of more than $150 billion. It pays a dividend, has been growing steadily over the years, and has many
If You Invested $20,000 in Amgen in 2014, This Is How Much You Would Have Today
Amgen (NASDAQ: AMGN) is one of the largest drug manufacturers in the world, with a market cap of more than $150 billion. It pays a dividend, has been growing steadily over the years, and has many
If You Invested $20,000 in Amgen in 2014, This Is How Much You Would Have Today
Amgen (NASDAQ: AMGN) is one of the largest drug manufacturers in the world, with a market cap of more than $150 billion. It pays a dividend, has been growing steadily over the years, and has many
Analysts Say Intellia Therapeutics Stock Could Rise 157% This Year, but Will It Happen?
Wall Street analysts are quite bullish about Intellia Therapeutics (NASDAQ: NTLA) stock. On average, they're estimating that it'll rise by around 157% within the next 12 months. In the context of
Why Sarepta Therapeutics Stock Is Soaring Today
Shares of Sarepta Therapeutics (NASDAQ: SRPT) were soaring 10.4% higher as of 10:58 a.m. ET on Friday. The big gain came after the biopharmaceutical company announced that the U.S. Food and Drug
Why Agenus Stock Plummeted by Nearly 30% on Its Stock Split News Today
Three otherwise innocuous words -- reverse stock split -- can cause much disappointment and even sow panic in an investor community. Shareholders of clinical-stage biotech Agenus (NASDAQ: AGEN)
2 Magnificent Growth Stocks to Buy With $500
Many people make it a New Year's resolution to start investing -- a laudable goal. The good news is that doing so doesn't require millions of dollars in the bank. Even with $500, a relatively modest
Is Vertex Pharmaceuticals Stock Too Expensive With a Price-to-Sales Ratio of 11x?
I've been a big fan of Vertex Pharmaceuticals (NASDAQ: VRTX), and the biotech stock has made me a lot of money throughout the years. Vertex continues to enjoy a virtual monopoly in treating cystic
Is Vertex Pharmaceuticals Stock Too Expensive With a Price-to-Sales Ratio of 11x?
I've been a big fan of Vertex Pharmaceuticals (NASDAQ: VRTX), and the biotech stock has made me a lot of money throughout the years. Vertex continues to enjoy a virtual monopoly in treating cystic
Is Vertex Pharmaceuticals Stock Too Expensive With a Price-to-Sales Ratio of 11x?
I've been a big fan of Vertex Pharmaceuticals (NASDAQ: VRTX), and the biotech stock has made me a lot of money throughout the years. Vertex continues to enjoy a virtual monopoly in treating cystic
Where Will Novavax Be in 10 Years?
After a brutal three-year period that saw its shares collapse by 99%, any remaining longtime shareholders of Novavax (NASDAQ: NVAX) are doubtlessly eager for the biotech to finally step out of the
Amgen Takes Aim at Novo Nordisk and Eli Lilly, but Is the Stock a Buy?
Amgen (NASDAQ: AMGN) is well on its way to producing a medicine for obesity that could one day rival the blockbuster weight-loss drugs like Wegovy and Zepbound made by the segment's monarchs, Novo
Amgen Takes Aim at Novo Nordisk and Eli Lilly, but Is the Stock a Buy?
Amgen (NASDAQ: AMGN) is well on its way to producing a medicine for obesity that could one day rival the blockbuster weight-loss drugs like Wegovy and Zepbound made by the segment's monarchs, Novo
Amgen Takes Aim at Novo Nordisk and Eli Lilly, but Is the Stock a Buy?
Amgen (NASDAQ: AMGN) is well on its way to producing a medicine for obesity that could one day rival the blockbuster weight-loss drugs like Wegovy and Zepbound made by the segment's monarchs, Novo
Zoetis (ZTS) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Zoetis (NYSE: ZTS)Q4 2023 Earnings CallFeb 13, 2024, 8:30 a.m. ET
Operator
Source Fool.com
Biogen (BIIB) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Biogen (NASDAQ: BIIB)Q4 2023 Earnings CallFeb 13, 2024, 8:00 a.m. ET
Operator
Source Fool.com
Biogen (BIIB) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Biogen (NASDAQ: BIIB)Q4 2023 Earnings CallFeb 13, 2024, 8:00 a.m. ET
Operator
Source Fool.com
Biogen (BIIB) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Biogen (NASDAQ: BIIB)Q4 2023 Earnings CallFeb 13, 2024, 8:00 a.m. ET
Operator
Source Fool.com
If You Invested $10,000 in Vertex Pharmaceuticals in 2014, This Is How Much You Would Have Today
It is customary to say that past success isn't a guarantee that a company will continue down that path -- a true statement. However, a corporation's track record provides vital information about its